Real‑life diagnostic and therapeutic approach to CLL/SLL in tuscany: the 2025 consensus - PubMed
3 days ago
- #Targeted Therapies
- #Chronic Lymphocytic Leukemia
- #Diagnostic Approaches
- The article discusses the real-life diagnostic and therapeutic approaches to Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) in Tuscany, as per the 2025 consensus.
- Key targeted therapies mentioned include Acalabrutinib, Ibrutinib, Pirtobrutinib, Venetoclax, and Zanubrutinib, focusing on BCL-2 and BTK pathways.
- References highlight significant studies and updates on CLL epidemiology, pathogenesis, diagnosis, and therapy, including works by Hallek M and others.
- The article emphasizes the importance of reproducible diagnosis of CLL by flow cytometry, as per European research initiatives.
- No competing interests were declared by the authors, ensuring unbiased presentation of information.